Table: Anges - 6-MTH group results
Jul 31 (Reuters)-
Anges, Inc.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months ended 6 months ended Year to
Jun 30, 2017 Jun 30, 2016 Dec 31, 2017
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 169 mln 169 mln 360 mln
(-0.3 pct) (-29.3 pct)
Operating loss 1.70 loss 2.80 loss 3.40
Recurring loss 1.70 loss 2.82 loss 3.40
Net loss 2.30 loss 2.83 loss 3.40
EPS loss 31.27 yen loss 47.63 yen loss 46.23 yen
Ann Div NIL NIL
-Q2 div NIL NIL
-Q4 div NIL NIL
NOTE - Anges, Inc..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4563.T
((Tokyo Headline News Desk +813 6441 1812))
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001